跳至主要内容
临床试验/NCT01040286
NCT01040286已完成2 期

The Efficacy and Safety of Flurbiprofen Chip Versus Chlorhexidine Chip (Periochip®) in Therapy of Adult Chronic Periodontitis

Dexcel Pharma Technologies Ltd.1 个研究点 分布在 1 个国家开始时间: 2009年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
试验地点
1
主要终点
Mean Probing Pocket Depth reduction

研究概览

简要总结

The purpose of the study is to assess efficacy and safety of Flurbiprofen Chip versus Chlorhexidine chip (Periochip®) in therapy of adult chronic periodontitis.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
21 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Signed and dated informed consent form
  • Good general health
  • Male or female subjects aged >21 years old
  • Availability for the 9 week duration of the study
  • Chronic periodontal disease on natural teeth characterized by the presence of at least 2 teeth with periodontal pockets of 5-9 mm in depth (potential target teeth) demonstrating bleeding on probing without involving the apex of the tooth and confirmed by dental X-ray.
  • Females of childbearing potential must be non-pregnant and non-lactating at entry and agree to use an adequate method (Oral or parenteral hormonal contraceptive; Intrauterine device; barrier and spermicide) of birth control during the study.

排除标准

  • An existing aggressive periodontitis.
  • Presence of oral local mechanical factors that could (in the opinion of the investigator) influence the outcome of the study.
  • Presence of orthodontic appliances, or any removable appliances, that impinge on the tissues being assessed.
  • Soft or hard tissue tumours of the oral cavity.
  • Presence of dental implant adjacent to target tooth.
  • Presence of more than 2 adjacent periodontal pockets on the same potential target tooth.
  • Periodontal pockets of more than 9 mm in depth, and/or with class 2 or 3 furcation involvement, on the potential target tooth.
  • Systemic antibiotic therapy or periodontal/mechanical/local delivery therapy within 6 weeks prior to study entry and throughout the study duration.
  • History of allergy to chlorhexidine, flurbiprofen or to other non-steroidal anti-inflammatory drugs (NSAIDs).
  • Subjects taking Phenytoin, calcium channel blockers drugs (CCBs) and/or cyclosporine, which might influence the pattern of tissue response.
  • Subjects treated with non-steroidal anti-inflammatory drugs (NSAIDs) within 14 days prior to entry into the study and throughout the study duration.
  • Presence of the following conditions: Type 1 diabetes, major recurrent aphtae, stomatitis, abscesses and related oral pathologies.
  • The presence of any medical or psychiatric condition that in the opinion of the investigator could affect the successful participation of the subject in the study.
  • Subject participates in any other clinical study 30 days prior to the start of the study and throughout the study duration.
  • Subject uses chlorhexidine oral rinses/ mouthwashes on a regular basis.

研究组 & 干预措施

Flurbiprofen Chip

Experimental

干预措施: Flurbiprofen (Drug)

Chlorhexidine chip

Active Comparator

干预措施: Chlorhexidine (Drug)

结局指标

主要结局

Mean Probing Pocket Depth reduction

时间窗: 8 weeks

次要结局

  • clinical attachment levels (CAL) and bleeding on probing (BOP)(8 weeks)

研究者

申办方类型
Industry

研究点 (1)

Loading locations...

相似试验